Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

1/20/2022
Press Release
Pandemic Speeds Adoption of Digitally Integrated Ophthalmic Diagnostics, While Slowing Supply Chain
Pandemic Speeds Adoption of Digitally Integrated Ophthalmic Diagnostics, While Slowing Supply Chain

COVID-19 removed barriers to the adoption of digital technologies, especially related to patient care, as the world adapted to ever-shifting norms, boosting the ophthalmic diagnostic device market....

1/20/2022
CataractIOLNewsletter
2021 in Review: US PC-IOL Market Share Surpasses 10 Percent in 2021, Surgeons Report
2021 in Review: US PC-IOL Market Share Surpasses  10 Percent in 2021, Surgeons Report

One in 10 US cataract surgery patients chose presbyopia-correcting IOLs (PC-IOLs) in 2021, breaking the 10 percent barrier for the first time ever in the country. Market Scope estimates that PC-IOL...

1/20/2022
DealsFundingNewsletter
Venture Capital Investment in Ophthalmology Reaches Record High in 2021
Venture Capital Investment in Ophthalmology Reaches Record High in 2021

Venture capital investments in ophthalmology exceeded $1.8 billion in 2021, setting a new record for VC investments in ophthalmic companies and technologies. Ophthalmic deals in 2021 surpassed $8 b...

1/20/2022
DeviceNewsletterPharma
60 Emerging Firms Report in 2021 That They are Targeting Ophthalmic Market
60 Emerging Firms Report in 2021 That They are Targeting Ophthalmic Market

Sixty companies revealed in in 2021 their intent to enter the ophthalmic market. Market Scope categorizes such firms as “emerging” companies. Those in 2021 range from developers of AI-based diagnos...

1/20/2022
DealsDeviceNewsletter
Ardian to Sell Stake in Schwind to Adagia
Ardian to Sell Stake  in Schwind to Adagia

Ardian will sell its majority stake in ophthalmic device maker Schwind eye-tech-solutions GmbH to Adagia Partners, the France-based private equity firms announced Dec. 21. No financial details were...

1/20/2022
AcquisitionsGene TherapyNewsletterRetina
Novartis to Acquire Gene Therapy Company Gyroscope for $800 Million, Milestones
Novartis to Acquire Gene Therapy Company Gyroscope for $800 Million, Milestones

Swiss company Novartis reported Dec. 22 that it had agreed to acquire UK-based ophthalmic gene therapy company Gyroscope Therapeutics. Gyroscope has been developing GT005, an AAV2-based one-time ge...

1/20/2022
AcquisitionsNewsletterRetina
Genentech, Lineage to Partner on Future Development of OpRegen RPE Cell Therapy
Genentech, Lineage to Partner on Future Development of OpRegen RPE Cell Therapy

Lineage Cell Therapeutics announced Dec. 20 that it had entered into an exclusive worldwide collaboration and license agreement with Genentech, a member of the Roche group, for the development and ...

1/20/2022
GlaucomaNewsletterRegulation
Glaukos Announces FDA 510(k) Clearance of iPrime System for Glaucoma Surgery
Glaukos Announces FDA 510(k) Clearance of iPrime System for Glaucoma Surgery

Glaukos announced Jan. 6 that the US FDA had granted 510(k) clearance for the company’s iPrime viscodelivery system. The San Clemente, California, company did not indicate when the system would be ...

1/20/2022
Dry EyeGlaucomaNewsletterPresbyopia
Glaukos Enrolls First Patients in Phase II Trials of Eyelid Creams for Dry Eye, Presbyopia
Glaukos Enrolls First Patients in Phase II Trials of Eyelid Creams for Dry Eye, Presbyopia

Glaukos announced Jan. 11 that it had achieved two clinical milestones with drug candidates utilizing its iLution transdermal eyelid cream platform. The San Clemente, California, company reported t...

1/20/2022
NewsletterRegulation
Select US FDA Approvals and Clearances in December 2021
Select US FDA Approvals and Clearances in December 2021

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in December 2021, according to the agency’s database. Notably, Sight Sciences’ TearCare system gai...

1/20/2022
DealsNewsletter
Bausch Health Files IPO Paperwork Ahead of Planned Spinout of Bausch + Lomb
Bausch Health Files IPO Paperwork Ahead of Planned Spinout of Bausch + Lomb

Bausch Health filed paperwork Jan. 13 for an initial public offering as part of its planned spinout of its Bausch + Lomb eye care business in 2022. The company first reported the intended separatio...

1/20/2022
FundingNewsletter
BVI Owner TPG Leads Latest Fundraising with $1 Billion Initial Public Offering
BVI Owner TPG Leads Latest Fundraising with $1 Billion Initial Public Offering

TPG Partners, headquartered in Fort Worth, Texas, led recent fundraising efforts by ophthalmic companies, with a $1 billion initial public offering. Funding for the past four weeks totaled $1.58 bi...

Past News Stories

1/20/2022
IndustryNewsletter
2021 in Review: Surgeon and Corporate Rankings of Market Scope's Top 10 Stories for the Year
2021 in Review: Surgeon and Corporate Rankings of Market Scope's Top 10 Stories for the Year

Market Scope polled surgeons and corporate clients in January 2022 on how they would rank our selections for the top 10 stories of 2021. Their responses appear below. ----- 2021 in Review: US PC-IO...

1/20/2022
COVID-19CataractNewsletterSurgical
2021 in Review: Practices Continue to Recover from Pandemic and Patient Backlogs
2021 in Review: Practices Continue to Recover from Pandemic and Patient Backlogs

Practices continued to fight rolling waves of virus variants and their impact on patient lives and surgical plans in 2021, while still trying to address and monitor patients whose treatments or vis...

1/20/2022
CataractNewsletterRegulationSurgical
2021 in Review: AAO, ASCRS Tangle with Aetna Over Preapproval of Cataract Surgery
2021 in Review: AAO, ASCRS Tangle with Aetna Over Preapproval of Cataract Surgery

Aetna, the third-largest insurer in the US, began requiring prior authorization of all cataract surgeries July 1, over strong opposition from the American Academy of Ophthalmology (AAO) and America...

1/20/2022
NewsletterPharmaPresbyopiaRefractive
2021 in Review: First Approved Presbyopia Drop Draws Interest Due to Market Potential
2021 in Review: First Approved Presbyopia Drop Draws Interest Due to Market Potential

The US FDA’s approval of Allergan’s Vuity, the first pharmacological treatment for presbyopia, in October 2021 ended years of anticipation for such a product. The approval was based on data from tw...

1/20/2022
DiagnosticNewsletterSurgicalTelehealth
2021 in Review: Enhanced Digital Products are Positive Result of Pandemic
2021 in Review: Enhanced Digital Products are Positive Result of Pandemic

Ophthalmic industry leaders signaled a new era in innovation in 2021, devoting significant resources to digital products and services, especially the integration of devices and existing digital pla...

1/20/2022
DeviceGlaucomaNewsletterRegulationSurgical
2021 in Review: More Surgical Options for Advanced Glaucoma Approach Finish Line
2021 in Review: More Surgical Options for Advanced Glaucoma Approach Finish Line

Several glaucoma surgical devices designed to treat more advanced stages of disease moved closer to US commercialization in 2021, while surgeons speaking at various meetings urged industry to focus...

1/20/2022
NewsletterPharmaRegulationRetina
2021 in Review: Genentech Gains Approval for Lucentis Port Delivery System
2021 in Review: Genentech Gains Approval for Lucentis Port Delivery System

Genentech’s US approval of the Lucentis Port Delivery System—dubbed Susvimo—in October 2021 gave the ophthalmic market a first-of-its-kind drug delivery system for retinal disease. The permanent, r...

1/20/2022
Dry EyeNewsletterPharmaRegulation
2021 in Review: FDA Approves Oyster Point’s Novel Treatment for Dry Eye
2021 in Review: FDA Approves Oyster Point’s Novel Treatment for Dry Eye

A new treatment for dry eye provided a novel delivery pathway when it gained US approval in October 2021. Tyrvaya (varenicline solution) nasal spray from Oyster Point Pharma is the first and only n...

1/20/2022
COVID-19MeetingNewsletter
2021 in Review: Vaccines Allow Return of Ophthalmic Meetings, But Success Uneven
2021 in Review: Vaccines Allow Return of Ophthalmic Meetings, But Success Uneven

The return of ophthalmic meetings in 2021 mirrored the ongoing global struggle with COVID-19 and surges associated with the emergence of the delta and omicron variants. Physical meetings didn’t ret...

1/20/2022
ChinaDealsNewsletter
2021 in Review: Deals Bring More Western Ophthalmic Technologies to China
2021 in Review: Deals Bring More Western Ophthalmic Technologies to China

The deals that Chinese companies made to acquire rights to sell products in China was not so much a top story in 2021 as an element of many stories. Market Scope noted in its newsletters in 2021 th...

1/20/2022
CataractInstrumentsNewsletterRetinaSurgical
DORC Increases Focus on Cataract Surgery with WEFIS Partnership
DORC Increases Focus on Cataract Surgery  with WEFIS Partnership

DORC International and WEFIS GmbH announced Jan. 12 that they had formed a new strategic partnership to develop cataract surgical instruments for use with DORC’s EVA platform and EQUIPHACO range of...

1/20/2022
MicroscopesNewsletter
Innovation to Drive Global Ophthalmic OR Microscope Market for 4.5 Percent Growth
Innovation to Drive Global Ophthalmic  OR Microscope Market for 4.5 Percent Growth

Sales of ophthalmic operating room (OR) microscopes in 2021 were dampened by the effects of the COVID-19 pandemic in the short term. Still, manufacturers continued to innovate and produce advanced ...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more